Attana AB
NNGM:ATANA0.00
SEK
0.00
(0.00%)
Attana AB
NGM:ATANA
(Nordic Growth Market)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Attana AB is a Sweden-based life science and biotechnology company that specializes in the development, manufacturing, and commercialization of proprietary label-free biosensor systems and bioanalytical services for molecular interaction research. Founded in 2002 and headquartered in Stockholm, Sweden, the company operates across the European, Asian, and North American life science markets, serving pharmaceutical corporations, biotechnology enterprises, contract research organizations, and academic institutions. Attana AB conducts its business through two principal divisions, Attana Life Science and Attana Diagnostics, offering a commercial portfolio that comprises analytical biosensor instruments utilizing proprietary Quartz Crystal Microbalance technology, including the flagship Attana Cell 250 third-generation analytical biosensor for real-time kinetic analysis of molecular interactions on living cells, tissues, and serum, alongside the Attana Cell 200 instrument platform; specialized biosensor consumables, including functionalized sensor chips, surface chemistry kits, biochemical reagents, and assay buffers; diagnostic solutions, including the Attana Virus Analytics platform for in vitro diagnostic antibody quantification, quality determination, and immune response profiling in biological samples; and comprehensive contract research organization services, including drug candidate screening, antibody characterization, epitope mapping, binding affinity determination, kinetic profiling, and immunogenicity testing. In recent operational developments, Attana AB has expanded its commercialization strategy by scaling its contract research organization operations and implementing an instrument rental business model to broaden access to its Quartz Crystal Microbalance analysis platforms among drug development partners. The company has also executed automated platform upgrades across its installed Attana Cell 250 base, secured ongoing service collaborations with biotechnology clients, and completed rights issues and warrant utilization rounds between 2024 and 2026 to finance global sales expansion and scale instrument deployment.